Item 8.01. Other Events

On October 30, 2009, Geron Corporation (the "Company") publicly disseminated a press release announcing the Company's plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury. The plan is expected to enable Geron to re-initiate the Phase I clinical trial of GRNOPC1 in patients with complete thoracic spinal cord injury. The Company's IND (Investigational New Drug application) for spinal cord injury is currently on clinical hold.

The foregoing description is qualified in its entirety by reference to the Company's Press Release dated October 30, 2009, a copy of which is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

(c) Exhibits

99.1 Press release dated October 30, 2009.

---